Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …

Background Lenalidomide and bortezomib frontline exposure has raised a growing need for
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …

The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Teclistamab and other B-cell maturation antigen (BCMA)–targeting bispecific antibodies
(BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) …

Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-
19 infection and associated complications due to their immunocompromised state, the older …

Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown
unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However …

Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

3. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-
1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress …